作者: David Greenberg , Noga Givon-Lavi , Shalom Ben-Shimol , Jacob Bar Ziv , Ron Dagan
DOI: 10.1016/J.VACCINE.2015.06.062
关键词: Pediatrics 、 Pneumococcal conjugate vaccine 、 Medicine 、 World health 、 Pneumonia 、 Population 、 Community-acquired pneumonia 、 Current analysis 、 Bacterial disease
摘要: Abstract Background Alveolar community-acquired pneumonia (A-CAP) is mostly considered a bacterial disease, mainly pneumococcal. This study was conducted to document the impact of sequential 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7; PCV13) on emergency room hospitalization for A-CAP among children Methods an ongoing prospective population-based in southern Israel. The current analysis spans over period July 2002 through June 2013. defined using World Health Organization (WHO)’s criteria radiologically-confirmed pneumonia. PCV7 introduced Israel 2009 gradually replaced by PCV13 November 2010. Pneumococcal vaccine (PCV) calculated comparing incidences during 3 pre-defined periods: pre-PCV (2002–2008), (2010–2011) (2012–2013). Results Overall, 10,142 episodes occurred. annual (per 1,000 inhabitants) vs. 32% hospitalized period). While 12–23 months significant decline observed periods, declines rates were only Conclusions A moderate hospital visits